MEN1 and acute myeloid leukemia: Promising results from a similar phase‐I/II trial (KOMET‐001) assessing the oral Menin inhibitor Ziftomenib (KO‐539, developed from MI‐3454) in 83 heavily pretreated R/R AML patients (median number of prior therapies: 3; previous allogeneic SCT: 31%) were also recently published.